Investigation in Targeted Drug Delivery to Lymphatic System
Neoplasm metastasis is a basic biological characteristic for malignant tumor and an important reason why most cancers remains incurable and fatal, which occurs via both blood land lymphatic vessels where lymphatic metastasis plays the main roles. Although prevention of neoplasm metastasis sounds perfect, lymphatic targeted treatment is of more practical significance considering the miserable fact that metastasis has already taken place in more than 60% cancer patients on first visit. To date most researches and clinical applications of lymphatic targeted drug delivery systems are still focused on imaging diagnostics, mainly including particulates (lymphatic imaging agents based on radioactive nuclide-labeled liposomes, micelles, sulfide and antimony sulfide colloid, polyamine/poloxamer and PEG/PEO surface-modified nanoparticles, Gd-DTPA-PEO-PE micelles, superfine paramagnetic iron oxide particles and lymphatic contrast agents surface-modified with hydrophilic PEG or polylysine) and macromolecular polymers or conjugates (lymphatic imaging agents based on radioactive nuclide-labeled dextrans and related derivatives, antibodies and related Fab fragments, human serum albumin and lymphatic contrast agents based on Gd-DTPA-dextran). Unfortunately no breakthrough progress has been made in lymphatic targetd drug delivery systems for treatment of neoplasm metastasis and most researches still stay in the research stage. Researches have involved many drug delivery systems including macromolecule-drug conjugates, liposomes, nanoparticles, micelles, activated carbon and emulsions.
Lu Weiyue
Pharmaceutical National Key Subject, School of Pharmcy, Fudan University
国际会议
International Symposium on Crystal Engineering and Drug Delivery System 2009(2009晶体工程与药物传送系统国际会议)
天津
英文
353-354
2009-09-05（万方平台首次上网日期，不代表论文的发表时间）